ArticleAlzheimer's & dementia (New York, N. Y.)2019
Institutionalization risk and costs associated with agitation in Alzheimer's disease.
Article in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease.Journal of geriatric psychiatry and neurology · 2026Trial
- Brexpiprazole for agitation in clinically relevant patient subgroups: aCurrent medical research and opinion · 2025Trial
- Longitudinal Impact of Agitation and Aggression Symptoms on Societal Costs in Alzheimer's Disease: A Focus on Informal Care and Socioeconomic Disparities.International journal of geriatric psychiatry · 2026Observational
- Baicalin and CNS-related diseases: new insights into neuroprotective potentials based on underlying mechanisms.Biochemistry and biophysics reports · 2026Review
- Observational
- Feasibility of the tailored activity program to bridge hospital and community care for people living with dementia and behavioral disorders: The "Continu-A-Mente" project.BMC geriatrics · 2026Article
- Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials.Clinical drug investigation · 2026Article
- Neuropsychiatric symptoms in mild cognitive impairment and early Alzheimer's disease: Clinical pattern and diagnostic implications.AIMS neuroscience · 2025Review
- Physician and professional caregiver perspectives on meaningful change in agitation behaviors in Alzheimer's dementia: Insights from qualitative interviews.Frontiers in dementia · 2025Article
- Behavioral and Psychological Symptoms of Dementia and Mortality Risk Among People With Cognitive Impairment: An 8-year Longitudinal Study From the NCGG-STORIES.Journal of epidemiology · 2024Article
- Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia.Journal of health economics and outcomes research · 2024Article
- Diagnosis of behavioral symptoms as a predictor of institutionalization among Medicaid patients with dementia.BMC geriatrics · 2023Article
- Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.JAMA neurology · 2023Article
- Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease.JAMA network open · 2023Article
- Paid Care Services and Transitioning out of the Community Among Black and White Older Adults With Dementia.The journals of gerontology. Series B, Psychological sciences and social sciences · 2023Article
- Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.Frontiers in neuroscience · 2023Review
- Management of Agitation in Behaviours That Challenge in Dementia Care: Multidisciplinary Perspectives on Non-Pharmacological Strategies.Clinical interventions in aging · 2023Article
- The Humanistic and Economic Burden of Alzheimer's Disease.Neurology and therapy · 2022Review
- Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2022Review
- Baicalin Attenuated ABioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionAgitation in individuals with Alzheimer's disease (AD) may predict institutionalization. This study assessed the incremental risk and costs associated with agitation in individuals with AD.
methodsA retrospective analysis of the National Alzheimer's Coordinating Center Uniform Data Set (June 2005-February 2018) was conducted. Incremental risk of institutionalization associated with agitation was estimated and used with the number of institutionalized individuals with AD and agitation and costs of living by residential setting in the United States (literature-based), to estimate incremental institutionalization costs.
resultsThe analysis included 11,348 individuals with AD: 6603 (58.2%) with and 4745 (41.8%) without agitation. Compared with individuals without agitation, those with agitation were 20% more likely to be institutionalized (odds ratio = 1.20; 95% CI = 1.08-1.33). Total incremental cost of institutionalization associated with agitation was $4.3 billion ($50,588/individual). DISCUSSION: Agitation is associated with a higher risk of institutionalization among patients with AD, which translates into a substantial economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.